title: Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.
abstract: Although CPT-I (carnitine palmitoyltransferase-I) is generally regarded to present a major rate-controlling site in mitochondrial beta-oxidation, it is incompletely understood whether CPT-I is rate-limiting in the overall LCFA (long-chain fatty acid) flux in the heart. Another important site of regulation of the LCFA flux in the heart is trans-sarcolemmal LCFA transport facilitated by CD36 and FABPpm (plasma membrane fatty acid-binding protein). Therefore, we explored to what extent a chronic pharmacological blockade of the LCFA flux at the level of mitochondrial entry of LCFA-CoA would affect sarcolemmal LCFA uptake. Rats were injected daily with saline or etomoxir, a specific CPT-I inhibitor, for 8 days at 20 mg/kg of body mass. Etomoxir-treated rats displayed a 44% reduced cardiac CPT-I activity. Sarcolemmal contents of CD36 and FABPpm, as well as the LCFA transport capacity, were not altered in the hearts of etomoxir-treated versus control rats. Furthermore, rates of LCFA uptake and oxidation, and glucose uptake by cardiac myocytes from etomoxir-treated rats were not different from control rats, neither under basal nor under acutely induced maximal metabolic demands. Finally, hearts from etomoxir-treated rats did not display triacylglycerol accumulation. Therefore CPT-I appears not to present a major rate-controlling site in total cardiac LCFA flux. It is likely that sarcolemmal LCFA entry rather than mitochondrial LCFA-CoA entry is a promising target for normalizing LCFA flux in cardiac metabolic diseases.
authors.affiliation: Department of Molecular Genetics, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands. j.luiken@gen.unimaas.nl
authors.forename: Joost J F P
authors.initials: JJ
authors.lastname: Luiken
authors.forename: Hanneke E C
authors.initials: HE
authors.lastname: Niessen
authors.forename: Susan L M
authors.initials: SL
authors.lastname: Coort
authors.forename: Nicole
authors.initials: N
authors.lastname: Hoebers
authors.forename: Will A
authors.initials: WA
authors.lastname: Coumans
authors.forename: Robert W
authors.initials: RW
authors.lastname: Schwenk
authors.forename: Arend
authors.initials: A
authors.lastname: Bonen
authors.forename: Jan F C
authors.initials: JF
authors.lastname: Glatz
mesh_terms: D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D015153:Blotting, Western; D002334:Carnitine O-Palmitoyltransferase / Q000378:metabolism*; D002478:Cells, Cultured; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation / Q000187:drug effects; D004852:Epoxy Compounds / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism*; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D051381:Rats; D014280:Triglycerides / Q000378:metabolism
chemical_list: D004852:Epoxy Compounds; D005227:Fatty Acids; D014280:Triglycerides; D002334:Carnitine O-Palmitoyltransferase; C054207:etomoxir